

assert that Groups I and II are linked so as to form a single general inventive concept under PCT Rule 13.1, and thus should be examined together. MPEP Appendix AI (the PCT Administrative Instructions) explicitly recognizes that unity of invention exists between a protein and the DNA sequence encoding that protein:

Example 17

Claim 1: Protein X

Claim 2: DNA sequence encoding protein X.

Expression of the DNA sequence in a host results in the production of a protein which is determined by the DNA sequence. The protein and the DNA sequence exhibit corresponding special technical features. Unity between claims 1 and 2 is accepted.

MPEP Appendix AI, at AI-60 (emphasis added). *See also* MPEP § 1850 at 1800-61 (accepting the examples in Annex B of the Administrative Instructions as examples of unity of invention). Thus, the Examiner's assertion on page 3 of the Office Action that the inventions of Groups I and II do not relate to a single general inventive concept directly conflicts with the established rules for unity of invention practice. At the very least, unity of invention exists between Groups I and II of the present invention, and those groups must be examined together. See PCT Article 27(1) ("No national law shall require compliance with requirements relating to the form or contents of the international application different from or additional to those which are provided for in this Treaty and the Regulations.")

Accordingly, in view of MPEP § 1850, MPEP Appendix AI, PCT Article 27(1), and PCT Rule 13.1, Applicants submit that the instant restriction requirement does not comply with PCT Rule 13.1 regarding unity of invention. Applicants therefore respectfully request that the restriction requirement under §§ 121 and 372 be reconsidered and rewritten or withdrawn.

Applicants retain the right to petition from the restriction requirement under 37 C.F.R. § 1.144.

Conclusion

Entry of the above amendment is respectfully solicited. The Examiner is invited to call the undersigned at the phone number provided below if any further action by Applicants would expedite the examination of this application.

If there are any fees due in connection with the filing of this paper, please charge the fees to our Deposit Account No. 08-3425. If a fee is required for an extension of time under 37

C.F.R. § 1.136, such an extension is requested and the appropriate fee should also be charged to our Deposit Account.

Dated: May 13, 2004

Respectfully submitted,

By 

Mark J. Hyman

Registration No.: 46,789

HUMAN GENOME SCIENCES, INC.

14200 Shady Grove Road

Rockville, Maryland 20850

(240) 314-1224

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. § 1.8

1. Fax Cover Sheet
2. Fee Transmittal Sheet
3. Provisional Election Under 37 C.F.R. § 1.143 With Traverse And Amendment Under 37 C.F.R. § 1.111

I hereby certify that the above-listed correspondence is being facsimile transmitted to the United States Patent and Trademark Office on May 13, 2004.



Mark J. Hyman
Registration No.: 46,789
HUMAN GENOME SCIENCES, INC.
14200 Shady Grove Road
Rockville, Maryland 20850
(240) 314-1224